Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer [Studio randomizzato di fase III sull'ottimizzazione della combinazione di bevacizumab con FOLFOX/OXXEL nel trattamento dei pazienti affetti da carcinoma del colon-retto metastatico]

Trial Profile

Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer [Studio randomizzato di fase III sull'ottimizzazione della combinazione di bevacizumab con FOLFOX/OXXEL nel trattamento dei pazienti affetti da carcinoma del colon-retto metastatico]

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenoma; Colorectal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms OBELICS
  • Most Recent Events

    • 12 Sep 2017 Primary endpoint (Objective Response rate) has not been met, as per results presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top